AOD-9604
peptideevidence: emerging · v1.0.0Description
AOD9604 is a modified C-terminal fragment of human growth hormone (residues 176-191), studied in lipid metabolism research models. Lyophilized powder. Reconstitute with bacteriostatic water for in-vitro research. Store at -20°C. Certificate of Analysis attached to this listing.
Mechanism summary
Lipolytic and repair-related signaling.
How it works
AOD-9604 is a synthetic peptide that corresponds to the last 15 amino acids of human growth hormone (positions 177-191) with an additional tyrosine added for stabilization. The primary focus of research on AOD-9604 has been to investigate whether the fat-metabolism effects of growth hormone can be isolated from its muscle-building, blood-sugar, and IGF-1 effects. This peptide has been studied for its potential in fat loss, but there has also been some exploration into its effects on joint and cartilage health.
The mechanism of action of AOD-9604 remains largely unknown, which limits the ability to predict specific physiological effects in humans. However, it has been suggested that AOD-9604 may interact with the beta-3 adrenergic receptor, as indicated by preclinical studies that showed reduced body weight gain in obese mice and rats. The peptide's ability to promote fat loss without the associated side effects of full-length growth hormone is a key area of interest in ongoing research.
Despite the promising findings in animal studies, the lack of comprehensive human pharmacokinetic studies, particularly for subcutaneous administration, raises questions about the peptide's efficacy and safety in humans. The absence of long-term safety data and the need for further investigation into its mechanisms of action highlight the importance of caution when considering AOD-9604 for therapeutic use. [Source: Peptide Dosing Protocols]
In plain language
AOD-9604 is a synthetic peptide that may help with fat loss by mimicking certain effects of human growth hormone without the side effects. Its exact mechanism is not fully understood.
Reference details
Route(s)
subcutaneous
Tags
—
Active
yes
Product details · 10AD
Price
$94.99
Stock
out of stock
Mol. weight
1815.1 g/mol
Formula
C78H123N23O23S2
Purity
≥ 99%
CAS #
221231-10-3
Amino sequence: Tyr-hGH(177-191) fragment (AOD-9604)
Teton Labs product catalog · research-use compound data.
💉 Dosing — 3 references (verbatim from source · not a recommendation)
Dose
300 mcg SC daily (commonly AM, fasted)
Route
subcutaneous
Frequency
once daily
Duration
8-12 weeks
Cycle
8-12 week cycles
Reconstitution
Reconstitute with bacteriostatic water
Vial
Commonly 2 mg or 5 mg vials
Source: Practitioner Peptide Dosing Reference (commonly published ranges) — Compiled practitioner reference (internal_protocol)Source-backedProvider-reviewed
Dose
250-300 mcg
Route
subcutaneous or oral
Frequency
Once daily
Duration
8-12 weeks
Reconstitution
Bacteriostatic water
Source: Peptide Protocol Wiki (peptideprotocolwiki.com) (publication)Source-backedProvider-reviewed
Dose
Standard: 300-500 mcg/day · Low: 300 mcg · High: 500 mcg
Route
Subcutaneous injection
Frequency
daily
Duration
12-24 weeks
Cycle
Cycle context Phase 2 protocols ran 12-24 weeks.
Reconstitution
3.0 mL bacteriostatic water for a 5 mg vial
Source: Peptide Dosing Protocols (peptidedosingprotocols.com) (publication)Source-backedProvider-reviewed
Safety, contraindications & monitoring
Contraindications — who should avoid
- Anyone considering it should consult a qualified clinician before use.
Safety & side effects
- Higher doses were associated with more reports of headache, diarrhea, and gastrointestinal effects.
Monitoring & bloodwork
- Blood tests as needed.
Clinical evidence
- Intra-articular AOD-9604 injections improved cartilage scores and reduced lameness in a rabbit model. · Kwon and Park 2015
- AOD-9604 lost most of its fat-metabolism effect in mice missing the beta-3 adrenergic receptor. · Heffernan et al. 2001
- The largest Phase 2b trial did not show statistically significant weight loss versus placebo. · null
Source-backedProvider-reviewedApproved findings drawn from your sources — decision support, not medical advice.
Provider-only reference. This page does not constitute medical advice, a recommendation, or dosing guidance.